There are 2137 resources available
764P - Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: Longitudinal expression, transcriptome-level effects and modulation of chemosensitivity
Presenter: Sara Wahlin
Session: E-Poster Display
Resources:
Abstract
765P - Predicting survival in urothelial cancer patients after immunotherapy using real-world data
Presenter: Thiraviyam Elumalai
Session: E-Poster Display
Resources:
Abstract
766P - Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study
Presenter: Michal Mego
Session: E-Poster Display
Resources:
Abstract
768P - Prognostic score combining systemic inflammation index (SII) and PD-L1 +/- LDH in advanced urinary tract carcinoma patients treated with atezolizumab: Subanalysis in the Italian population of the SAUL study
Presenter: Sara Elena Rebuzzi
Session: E-Poster Display
Resources:
Abstract
767P - Neutrophil-to-lymphocyte ratio (NLR) and systemic inflammation index (SII) as prognostic factors in advanced urinary tract carcinoma patients treated with atezolizumab: Subanalysis of the Italian population of the SAUL study
Presenter: Sara Elena Rebuzzi
Session: E-Poster Display
Resources:
Abstract
769P - APOBEC signatures and high tumour mutational burden as predictors of clinical outcomes and response to therapy in patients with urothelial carcinoma
Presenter: Divya Natesan
Session: E-Poster Display
Resources:
Abstract
770P - Prognostic and predictive value of ribonucleotide reductase subunit family M1/M2 in urothelial carcinoma
Presenter: Jinan Guo
Session: E-Poster Display
Resources:
Abstract
772P - Phase Ib/II study of durvalumab plus guadecitabine in advanced clear cell renal cell cancer (ccRCC)
Presenter: Yousef Zakharia
Session: E-Poster Display
Resources:
Abstract
771P - Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer
Presenter: VADIM KOSHKIN
Session: E-Poster Display
Resources:
Abstract
773P - Cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy: Safety and preliminary activity of the open-label, single-arm, phase II ARCADIA trial
Presenter: Laura Marandino
Session: E-Poster Display
Resources:
Abstract